Search for Terms or Answers
Current ACR guidelines for the management of gout support anti-inflammatory prophylaxis, including colchicine, during urate lowering therapy initiation and uptitration. Aside from diarrhea, colchicine use is generally well tolerated, but its metabolism via the CYP3A4 cytochrome P450 enzyme pathway poses a potential risk of medication interaction. Statins are one of the most widely prescribed medication classes also metabolized by this pathway
Avacopan (Tavneos), the complement pathway inhibitor for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), appeared strongly effective in an Italian registry study -- a step, maybe, toward setting to rest questions about its efficacy, if not its safety.
After years of inactivity, therapeutic development for dermatomyositis has begun to move forward with several new therapies and therapeutic strategies.
The costs of GLP-1 agonists must come down in order to make these treatments available to the people who need them - including many people with rheumatologic diseases.
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
